Completed PHASE2 INTERVENTIONAL 1-arm NCT00125359

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer

Sponsor: Genentech, Inc.

Conditions Carcinoma, Non-small-cell Lung

Interventions erlotinib and bexarotene

Updated 8 times since 2017 Last updated: Dec 14, 2018 Started: Aug 31, 2005 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Non-small-cell Lung, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 8 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2019 — Jan 2021 [monthly]

Completed PHASE2
Dec 2018 — Feb 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Konstantin Dragnev
Ligand Pharmaceuticals

Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lebanon, United States
• New York, United States